Safety Study of Depigoid Vaccine Dermatophagoides Pteronyssinus or 50% Dermatophagoides Pteronyssinus / 50% Dermatophagoides Farinae (500 DPP/ml), to Treat Allergic Rhinitis or Rhinoconjunctivitis With or Without Asthma

NCT01591343 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

8

Enrollment

INDUSTRY

Sponsor class

Stopped Study halted by Sponsor

Conditions

Allergic Rhinitis
Rhinoconjunctivitis
Mild Persistent Asthma
Mild Intermittent Asthma

Interventions

BIOLOGICAL: Depigoid® (500 DPP/ml)

Sponsor

Laboratorios Leti, S.L.

Collaborators

[object Object]